Unexpected keys in cell biochemistry imaging: Some lessons from technetium-99m-sestamibi

Journal of Nuclear Medicine

Volumn 37, Issue 3, 1996, Pages 536-538

  Mariani, Giuliani ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

biocellular imaging; technetium 99m sestamibi

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ANTIBODY LABELING; ARTICLE; CELL COMPOSITION; CYTOLOGY; IMAGE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR SCINTISCANNING;

ANIMALS; CELLS; HEART; HUMANS; TECHNETIUM TC 99M SESTAMIBI; TUMOR CELLS, CULTURED;

EID: 0029925993     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Piwnica-Worms D, Kronauge JF, Holman BL, Davison A, Jones AG. Comparative myocardial uptake characteristics of hexakis (alkylisonitrile) technetium(I) complexes effect of lipophilicity. Invest Radiol 1989;24:25-29.
2. Rossetti C, Vanoli G, Paganelli G, et al Human biodistribution, dosimetry and clinical use of technetium(III)-99m-Q12. J Nucl Med 1994;35:1571-1580.
3. 99mTc Q-series complexes with ester functionality [Abstract]. J Nucl Med 1995;36(suppl.):17P.
4. Crankshaw CL, Marmion M, Burleigh BD, Deutsch E, Piwnica-Worms D. Nonreducible mixed ligand Tc(III) cations (Q complexes) are recognized as transport substrates by the human multidrug resistance (MDR) P-glycoprotein [Abstract]. J Nucl Med 1995;36(suppl.):130P.
5. Wackers FJT The maze of myocardial perfusion imaging protocols in 1994. J Nucl Cardiol 1994,1:180-188.
6. 99mTc complexes targeted to the multidrug resistance (MDR) P-glycoprotein [Abstract]. J Nucl Med 1995; 36(suppl.):27P-28P.
7. Mansi L, Rambaldi PF, La Provitera A, Di Gregorio F, Procaccini E. Tc-99m Tetrofosmin uptake m breast tumors [Abstract]. J Nucl Med 1995;36(suppl.):83P.
8. Ballinger JR, Bannerman J, Boxen I, et al. Accumulation of Tc-99m tetrofosmin in breast tumour cells in vitro: role of multidrug-resistance P-glycoprotein [Abstract]. J Nucl Med 1995;36(suppl.):202P
9. Kronauge JF, Chiu ML, Cone JS, et al. Comparison of neutral and cationic myocardial perfusion agents: characteristics of accumulation in cultured cells. Nucl Med Biol 1992;19 141-148.
10. Pasqualini R, Duatti A, Bellande E, et al. Bis(dithiocarbamato) nitrido technetium-99m radiopharmaceuticals. a class of neutral myocardial imaging agents J Nucl Med 1994;35:334-341
11. Piwnica-Worms D, Kronauge JF, Delmon L, Holman BL, Marsh JD, Jones AG. Effect of metabolic inhibition on technetium-99m-MIBI kinetics in cultured chick myocardial cells. J Nucl Med 1990,31:464-472.
12. Carvalho PA, Chiu ML, Kronauge JF, et al Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 1992;33:1516-1521.
13. Piwnica-Worms D, Kronauge JF. Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826-1838.
14. Chernoff DM, Strichartz GR, Piwnica-Worms D. Membrane potential determination in large unilamellar vesicles with haxakis(2-methoxyisobutyl-isonitrile)technetium(1). Biochim Biophys Acta 1993;1147:262-266.
15. Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990;50:2198-2202
16. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 1990;31:1646-1653.
17. Piwnica-Worms D, Kronauge JF, Chiu ML. Enhancement by tetraphenylborate of technetium-99m-MIBI uptake kinetics and accumulation in cultured chick myocardial cells J Nucl Med 1991;32:1992-1999.
18. 99mTc-sestamibi in cultured chick ventricular myocytes during ATP depletion. Circulation 1992;85:1531-1541
19. 99Tc NMR spectroscopy. Magn Res Imag 1994;12:641-652.
20. Cesani F, Ernst R, Walser E, Villanueva-Meyer J. Technetium-99m sestamibi imaging of a pancreatic VIPoma and parathyroid adenoma in a patient with multiple type I endocrine neoplasia. Clin Nucl Med 1994;19:532-534.
21. 99mTc sestamibi during routine cardiac imaging. Clin Nucl Med 1995;20:84-85.
22. 99mTc-sestamibi in tumor imaging. In: Freeman LM, ed. Nuclear Medicine Annual 1994 New York: Raven Press; 1994:181-234
23. Moscow JA, Cowan KH. Multidrug resistance. J Natl Cancer Inst 1988;80:14-20.
24. Goldstein LJ, Galski H, Fojo A, et al Expression of a multidrug resistance gene in human cancers J Natl Cancer Inst 1989,81:116-124.
25. Deuchars KL, Ling V. P-Glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 1989;16:156-165
26. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:155-199.
27. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993,53:977-984.
28. Rogan AM, Hamilton TC, Young RC, Klecker RW, Ozols RF. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 1984;224:994-996.
29. Ozols RF, Cunnian RE, Klecker RW, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987;5:641-647.
30. Miller TP, Grogan TM, Dalton WS, et al. P-Glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991;9:17-24.
31. Sonneveld P, Durian BG, Lokhorst HM, Marie J-P, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992;340.255-259.
32. Moretti JL, Caglar M, Duran-Cordobes M, Morere J-F. Can nuclear medicine predict response to chemotherapy? Eur J Nucl Med 1995,22:97-100.
33. Moretti JL, Caglar M, Boaziz C, Caillat-Vigneron N, Morere J-F. Sequential functional imaging with technetium-99m-hexakis-2-methoxyisobutylisonitrile and indium-111-octreotide: can we predict the response to chemotherapy in small cell lung cancer? Eur J Nucl Med 1995;22:177-180.
34. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, et al. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas Eur J Nucl Med 1995;22:434-442.
35. Ciarmiello A, Del Vecchio S, Potena MI, et al. Technetium-99m-sestamibi efflux and P-glycoprotein expression in human breast carcinoma [Abstract]. J Nucl Med 1995; 36(suppl.):129P.